Zoetis Inc. (NYSE:ZTS) Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,121,306 shares of the company’s stock after purchasing an additional 32,407 shares during the period. Natixis Advisors LLC’s holdings in Zoetis were worth $219,081,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ZTS. First Personal Financial Services purchased a new stake in shares of Zoetis in the 3rd quarter valued at $33,000. Capital Performance Advisors LLP purchased a new stake in Zoetis during the third quarter worth about $33,000. Quarry LP lifted its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares in the last quarter. LRI Investments LLC purchased a new position in shares of Zoetis in the first quarter valued at approximately $43,000. Finally, Fortitude Family Office LLC grew its holdings in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after purchasing an additional 222 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of Zoetis stock opened at $175.14 on Friday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm’s 50 day moving average is $187.09 and its two-hundred day moving average is $180.08. The firm has a market capitalization of $79.02 billion, a P/E ratio of 32.92, a P/E/G ratio of 2.68 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the business earned $1.36 EPS. Zoetis’s revenue for the quarter was up 11.6% compared to the same quarter last year. Research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.99%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ZTS shares. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Piper Sandler upped their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.